Donaldson Company and SurModics Announce Strategic Marketing and Distribution Relationship With Corning Life Sciences

May 11, 2006, 01:00 ET from Donaldson Company, Inc.

    MINNEAPOLIS, May 11 /PRNewswire-FirstCall/ -- Donaldson Company, Inc.
 (NYSE:   DCI) and SurModics, Inc. (Nasdaq:   SRDX) today announced a strategic
 marketing and distribution agreement with Corning Incorporated (NYSE:   GLW),
 through which Corning Life Sciences will provide worldwide marketing and
 distribution of nanofiber cell culture products for in vitro (laboratory
 based) cell culture research and drug discovery applications.
     The distribution agreement is intended to bring the SurModics-Donaldson
 jointly developed nanofiber products to customers more quickly by taking
 advantage of Corning Life Sciences' market leading position in plastic and
 glass labware for use in cell culture and drug discovery applications.
 Evaluations by multiple customers have demonstrated that the Ultra-Web(TM)
 Synthetic ECM (extracellular matrix) products mimic cell growth conditions
 that more closely resemble those found in the body (in vivo), leading to
 improved outcomes in cell culture, cell-based bioassays and other in vitro
 cell-related applications.
     "Corning Life Sciences is an outstanding partner to market and
 distribute the Ultra-Web Synthetic ECM technology into the cell culture and
 drug discovery marketplace," said Bruce Barclay, President and CEO of
 SurModics. "Corning Life Sciences' market leadership position will help
 accelerate the market adoption and penetration of this revolutionary
 technology. We are excited about working closely with Corning Life Sciences
 to capitalize on the full potential of this platform technology."
     "The Ultra-Web Synthetic extracellular matrix technology is a
 breakthrough synthetic technology and fits well with our growth vision for
 cell culture and drug discovery applications," said Mark Beck, Division
 Vice President and Deputy General Manager of Corning Life Sciences. "This
 agreement with SurModics and Donaldson is consistent with our commitment to
 bring the best technology in the right product formats to our customers."
     Donaldson and SurModics formed a joint development relationship in May
 2005, combining Donaldson's nanofiber technology and SurModics' surface
 modification technology to create synthetic nanofibrillar cell culture
 products. Donaldson and SurModics recently introduced the first jointly
 developed product as a cell culture insert based on the Ultra-Web Synthetic
 ECM technology. Moving forward, all three companies will continue to
 jointly develop a platform of products based on the technology.
     In collaboration with the inventor, Dr. Melvin Schindler, Department of
 Biochemistry and Molecular Biology, Michigan State University, and Dr.
 Sally Meiners of the Robert Wood Johnson Medical School of Piscataway, New
 Jersey, Donaldson and SurModics have demonstrated that the Ultra-Web
 technology provides enhanced cell culture results and more in vivo-like
 cell behavior with certain cells and cell types. Field tests also have
 shown that the Ultra-Web Synthetic ECM provides superior performance
 compared to variable biological matrices and hydrogels.
     SurModics, Donaldson, and Corning Life Sciences will target both basic
 cell biology research and cell-based high throughput screening (HTS)
 applications for drug discovery and development. Additional information
 about Donaldson Ultra-Web(TM) Synthetic ECM products can be found at .
     About Donaldson Company, Inc.
     Donaldson is a leading worldwide provider of filtration systems and
 replacement parts. Donaldson is a technology-driven company committed to
 satisfying customer needs for filtration solutions through innovative
 research and development. Donaldson serves customers in the diesel engine
 and industrial markets including in-plant air cleaning, compressed air and
 gas purification, power generation, disk drive filtration, off-road
 equipment and trucks. Our 11,000 employees contribute to the company's
 success at over 30 manufacturing locations around the world. Donaldson is a
 member of the S&P MidCap 400 Index and Donaldson shares are traded on the
 NYSE under the symbol DCI. Additional company information is available at .
     About SurModics, Inc.
     SurModics, Inc. is a leading provider of surface modification
 technologies in the areas of biocompatibility, site specific drug delivery,
 biological cell encapsulation, and medical diagnostics. SurModics partners
 with the world's foremost medical device, pharmaceutical and life science
 companies to bring innovation together for better patient outcomes. Recent
 collaborative efforts include the implementation of SurModics' Bravo(TM)
 drug delivery polymer matrix as a key component of the first-to-market
 drug-eluting coronary stent. SurModics is also active in the ophthalmology
 market with a sustained drug delivery system that is currently in human
 trials for treatment of retinal disease. A significant portion of
 SurModics' revenue is generated by royalties earned from the sale of our
 customers' commercial products. SurModics is headquartered in Eden Prairie,
 MN. More information about the company can be found at The content of SurModics' web site is not part of
 this release or part of any filings the company makes with the SEC.
     About Corning Incorporated
     Corning Incorporated ( ) is a diversified
 technology company that concentrates its efforts on high-impact growth
 opportunities. Corning combines its expertise in specialty glass, ceramic
 materials, polymers and the manipulation of the properties of light, with
 strong process and manufacturing capabilities to develop, engineer and
 commercialize significant innovative products for the telecommunications,
 information display, environmental, semiconductor, and life sciences
     Corning Life Sciences helps customers succeed by providing innovative,
 high-quality products and service in the areas of polymer science,
 biochemistry and molecular biology, glass melting and forming, surface
 modification and characterization science. Corning cell culture and assay
 labware products include tissue culture dishes, 6 and 24-well multiwell
 plates, 96, 384, and 1536-well microplates, roller bottles, flasks, and
 CellSTACK(R) Culture Chambers. The business' dedication to quality,
 technology, and innovation has enabled it to produce a comprehensive line
 of plastic laboratory disposables and reusable glassware that exceeds
 American Standard Testing Method (ASTM) standards for life science
     SurModics' Safe Harbor for Forward Looking Statements
     Certain statements contained in this press release may be deemed to be
 forward-looking statements under federal securities laws, and SurModics
 intends that such forward looking statements be subject to the safe harbor
 created thereby. Factors that may cause actual results to differ from the
 forward-looking statements include those described in the "Risk Factors"
 and other sections of SurModics' filings with the Securities and Exchange
 Commission. SurModics does not undertake an obligation to publicly update
 or revise any forward-looking statements, whether as a result of new
 information, future events or otherwise.
     Donaldson's Safe Harbor Statement
     The company desires to take advantage of the "safe harbor" provisions
 of the Private Securities Litigation Reform Act of 1995 (the "Act") and is
 making this cautionary statement in connection with such safe harbor
 legislation. This release, the Annual Report to Shareholders, any Form
 10-K, 10-Q or Form 8-K of the company or any other written or oral
 statements made by or on behalf of the company may include forward-looking
 statements, forecasts and projections which reflect the company's current
 views with respect to future events and financial performance but involve
 uncertainties that could significantly impact results. The words "believe,"
 "expect," "anticipate," "intends," "estimate," "forecast," "outlook,"
 "plan," "promises," "project," "should," "will be" and similar expressions
 are intended to identify "forward- looking statements" within the meaning
 of the Act.
     The company wishes to caution investors that any forward-looking
 statements are subject to uncertainties and other risk factors that could
 cause actual results to differ materially from such statements, including
 but not limited to risks associated with: currency fluctuations, commodity
 prices, world economic factors, political factors, the company's
 international operations, highly competitive markets, changes in product
 demand, and governmental laws and regulations. For a more detailed
 explanation, see the company's 2005 Form 10-K and most recent Form 10-Q
 filed with the Securities and Exchange Commission. The company wishes to
 caution investors that new factors emerge from time to time, and it is not
 possible for management to predict all such factors, nor can it assess the
 impact of each such factor on the business or the extent to which any
 factor, or a combination of factors, may cause actual results to differ
 materially from those contained in any forward-looking statements.
 Investors are further cautioned not to place undue reliance on such
 forward-looking statements as they speak only to the company's views as of
 the date the statement is made. The company undertakes no obligation to
 publicly update or revise any forward-looking statements.
     Corning Incorporated Forward-Looking and Cautionary Statements
     This press release contains forward-looking statements that involve a
 variety of business risks and other uncertainties that could cause actual
 results to differ materially. These risks and uncertainties include the
 possibility of changes or fluctuations in global economic and political
 conditions; tariffs, import duties and currency fluctuations; product
 demand and industry capacity; competitive products and pricing;
 manufacturing efficiencies; cost reductions; availability and costs of
 critical components and materials; new product development and
 commercialization; order activity and demand from major customers; capital
 spending by larger customers in the liquid crystal display industry and
 other businesses; changes in the mix of sales between premium and
 non-premium products; facility expansions and new plant start-up costs;
 possible disruption in commercial activities due to terrorist activity,
 armed conflict, political instability or major health concerns; ability to
 obtain financing and capital on commercially reasonable terms; adequacy and
 availability of insurance; capital resource and cash flow activities;
 capital spending; equity company activities; interest costs; acquisition
 and divestiture activities; the level of excess or obsolete inventory; the
 rate of technology change; the ability to enforce patents; product and
 components performance issues; changes in key personnel; stock price
 fluctuations; and adverse litigation or regulatory developments. These and
 other risk factors are identified in Corning's filings with the Securities
 and Exchange Commission. Forward-looking statements speak only as of the
 day that they are made, and Corning undertakes no obligation to update them
 in light of new information or future events.

SOURCE Donaldson Company, Inc.